Bullstory
May 21, 2026

PharmaResearch's5factory groundbreaking · HLB's solo booth at a U.S. cancer conference

PharmaResearch in Gangneung, its5factory groundbreaking has begun. HLB introduced new drugs for liver and bile duct cancers at its solo booth at a U.S. cancer conference. Hanmi Pharmaceutical is pursuing exports of a combination drug with Organon to Southeast Asia, in3types.

파마리서치214450—

Get free 파마리서치 email updates.

Bullstory sends one daily email when new analysis or important company news is available.


PharmaResearch's5factory groundbreaking · HLB's solo booth at a U.S. cancer conference

PharmaResearch2026 year 5 month 22 day announced that it had begun construction of its factory in Gangneung.5The company said the facility expansion is intended to meet domestic and global production demand. It said the groundbreaking was intended to supplement existing production capacity.

Around the same time, HLB introduced new drugs for liver and bile duct cancers at a U.S. cancer conference and operated a solo booth. The company said the event was an opportunity to highlight the drugs' potential for global expansion. The conference participation included clinical results and development plans.

Pony.ai said it is accelerating the commercialization of robotaxis in China. It said the expansion of commercial services and trial runs of related technologies are under way. The company disclosed plans to expand operations in China.

Asset manager Time has launched an ETF that includes global robotics-related stocks. The K Savings Bank has introduced a savings product with an annual4.7% interest rate. The two products were presented as tailored to demand for robotics and automation, and for personal deposits.

Plans to launch a crypto ETF in Thailand have been announced. This was accompanied by an explanation that competition to become a digital asset hub in Southeast Asia is accelerating. Discussions on related regulations and infrastructure expansion are also underway.

Hanmi Pharmaceutical said it plans to pursue exports to Southeast Asia of a combination drug developed with Organon, comprising3products. The company said it is discussing export destinations and contract procedures. It explained that the export push aims to expand sales across the region.

Sources: 국내언론,매일경제 산업,연합뉴스 경제

Bullstory synthesized this report from the linked sources. AI may have assisted the writing process. Check the original reports for factual confirmation.